»» Searching for " VEN309 "
 Related Search Tags:  Iferanserin Nasdaq:VTUS VEN309 Ventrus VentrusBiosciences VTUS
Showing Results 1-1 of 1 |  Sort by:     
Page 1 of 1  |  Go to page   
Welcome to CRWENewswire, Stocks to Watch. I am Shalika Jayasekera. Ventrus BioSciences Incorporated - symbol VTUS - reported that it has completed its acquisition of all rights and title to VEN 309 - iferanserin ointment for the treatment of symptomatic hemorrhoids - from the licensor, Sam Amer & Company. Based on a report by the National Institute of Diabetes and Digestive Kidney Diseases, the company estimates that symptomatic hemorrhoids currently affect approximately 12.5 million adults. Ventrus is a development stage specialty pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders. Thanks for joining me and have a great day! For CRWE Newswire, Stocks to watch, I’m Shalika Jayasekera
Ventrus Biosciences (VTUS)...
Categories: Videos 
Added: 184 days ago
By: karmastock
Runtime: 1m20s
Views: 114
 | Comments: 0
Not yet rated
Page 1 of 1  |  Go to page   
About Us   |   Terms of Use   |   Privacy Policy   |   Copyright Notes   |   Contact Us   |   Help   |      |   Back to the top of this page
Copyright © 2006-2007 bongoTYube. All rights reserved.    | Page created in 0.1144 seconds.